EU drug agency to finalise Acomplia review in July

(Reuters) - The EU watchdog had initially said it was likely to give a
view this month.




The close review of Acomplia's safety profile comes two
weeks after a U.S. advisory panel said the medicine should not
be approved in the world's biggest drugs market because it may
increase suicidal thinking and depression.


Read more at Reuters.com Government Filings News